Skip to main content
Clinical Trials/KCT0005531
KCT0005531Not yet recruiting未知

Improvement of lower urinary tract symptoms and incidence of retrograde ejaculation when 2.5mg or 5mg of Terazosin is administered to patients with benign prostatic hyperplaisa

Pusan National University Hospital0 sites142 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Not yet recruiting
Enrollment
142

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional Study

Eligibility Criteria

Ages
19(Year) to o Limit (—)
Sex
Male

Inclusion Criteria

  • 1) Adult male over 19 years old
  • 2) Those with an IPSS total score of 8 or more
  • 3) Those with a maximum urine velocity (Qmax) of less than 10mL/s
  • 4) Those who agreed to participate in this study by handwriting

Exclusion Criteria

  • 1) Those who are hypersensitive to a-blocker drugs
  • 2) Those with bladder neck stenosis or urinary tract stenosis
  • 3) Those with renal dysfunction (serum creatine concentration>2.0mg/dL)
  • 4) Those with severe liver disorder or medical history
  • 5) Those with severe cardiovascular disease
  • 6) Those with severe low blood pressure
  • 7) Others who are inadequate to participate in this research as the research director judges

Investigators

Similar Trials